LumiraDx Limited (NASDAQ: LMDXW) Stock Competitors & Peer Comparison
See LMDXW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LMDXW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LMDXW | $0.00 | +0.00% | 5.1M | -0.00 | -$2.93 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.70% |
| TMO | $656.58 | -2.98% | 242.8B | 28.35 | $23.16 | +0.28% |
| DHR | $215.61 | -2.53% | 151.5B | 27.01 | $7.98 | +0.70% |
| NTRA | $400.65 | -5.87% | 57.4B | -303.52 | -$1.32 | N/A |
| A | $169.33 | -1.14% | 47.8B | 29.15 | $5.81 | +0.60% |
| WAT | $436.43 | -0.84% | 42.9B | 31.90 | $13.68 | N/A |
| IQV | $259.98 | -2.30% | 42.8B | 21.45 | $12.13 | N/A |
| ILMN | $273.54 | -6.86% | 41.4B | 54.38 | $5.03 | N/A |
| IDXX | $515.41 | -2.21% | 40.7B | 36.25 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
LMDXW vs DHR-PB Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, LMDXW's ROE is -15.58%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, LMDXW is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
LMDXW vs TMO Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, TMO has a market cap of 242.8B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while TMO trades at $656.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas TMO's P/E ratio is 28.35. In terms of profitability, LMDXW's ROE is -15.58%, compared to TMO's ROE of +0.13%. Regarding short-term risk, LMDXW is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
LMDXW vs DHR Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, DHR has a market cap of 151.5B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while DHR trades at $215.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas DHR's P/E ratio is 27.01. In terms of profitability, LMDXW's ROE is -15.58%, compared to DHR's ROE of +0.08%. Regarding short-term risk, LMDXW is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
LMDXW vs NTRA Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, NTRA has a market cap of 57.4B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while NTRA trades at $400.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas NTRA's P/E ratio is -303.52. In terms of profitability, LMDXW's ROE is -15.58%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, LMDXW is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
LMDXW vs A Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, A has a market cap of 47.8B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while A trades at $169.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas A's P/E ratio is 29.15. In terms of profitability, LMDXW's ROE is -15.58%, compared to A's ROE of +0.20%. Regarding short-term risk, LMDXW is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check A's competition here
Waters Corporation (NYSE: WAT)
LMDXW vs WAT Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, WAT has a market cap of 42.9B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while WAT trades at $436.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas WAT's P/E ratio is 31.90. In terms of profitability, LMDXW's ROE is -15.58%, compared to WAT's ROE of +0.02%. Regarding short-term risk, LMDXW is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
LMDXW vs IQV Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, IQV has a market cap of 42.8B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while IQV trades at $259.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas IQV's P/E ratio is 21.45. In terms of profitability, LMDXW's ROE is -15.58%, compared to IQV's ROE of +0.22%. Regarding short-term risk, LMDXW is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check IQV's competition here
Illumina, Inc. (NASDAQ: ILMN)
LMDXW vs ILMN Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, ILMN has a market cap of 41.4B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while ILMN trades at $273.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas ILMN's P/E ratio is 54.38. In terms of profitability, LMDXW's ROE is -15.58%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, LMDXW is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
LMDXW vs IDXX Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, IDXX has a market cap of 40.7B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while IDXX trades at $515.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas IDXX's P/E ratio is 36.25. In terms of profitability, LMDXW's ROE is -15.58%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, LMDXW is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
LMDXW vs MTD Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, MTD has a market cap of 31B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while MTD trades at $1,533.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas MTD's P/E ratio is 35.21. In terms of profitability, LMDXW's ROE is -15.58%, compared to MTD's ROE of -12.00%. Regarding short-term risk, LMDXW is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
LMDXW vs LH Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, LH has a market cap of 25.6B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while LH trades at $311.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas LH's P/E ratio is 18.50. In terms of profitability, LMDXW's ROE is -15.58%, compared to LH's ROE of +0.12%. Regarding short-term risk, LMDXW is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
LMDXW vs DGX Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, DGX has a market cap of 25.2B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while DGX trades at $228.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas DGX's P/E ratio is 22.53. In terms of profitability, LMDXW's ROE is -15.58%, compared to DGX's ROE of +0.14%. Regarding short-term risk, LMDXW is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
LMDXW vs GH Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, GH has a market cap of 22.9B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while GH trades at $170.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas GH's P/E ratio is -48.91. In terms of profitability, LMDXW's ROE is -15.58%, compared to GH's ROE of +2.11%. Regarding short-term risk, LMDXW is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
LMDXW vs EXAS Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas EXAS's P/E ratio is -95.37. In terms of profitability, LMDXW's ROE is -15.58%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, LMDXW is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check EXAS's competition here
Revvity, Inc. (NYSE: RVTY)
LMDXW vs RVTY Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, RVTY has a market cap of 17.1B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while RVTY trades at $153.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas RVTY's P/E ratio is 28.66. In terms of profitability, LMDXW's ROE is -15.58%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, LMDXW is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
LMDXW vs ILMNV Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas ILMNV's P/E ratio is N/A. In terms of profitability, LMDXW's ROE is -15.58%, compared to ILMNV's ROE of N/A. Regarding short-term risk, LMDXW is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
LMDXW vs MEDP Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, MEDP has a market cap of 16.8B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while MEDP trades at $602.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas MEDP's P/E ratio is 35.34. In terms of profitability, LMDXW's ROE is -15.58%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, LMDXW is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check MEDP's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
LMDXW vs CRL Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, CRL has a market cap of 14.7B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while CRL trades at $304.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas CRL's P/E ratio is 30.81. In terms of profitability, LMDXW's ROE is -15.58%, compared to CRL's ROE of -0.08%. Regarding short-term risk, LMDXW is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
LMDXW vs PKI Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas PKI's P/E ratio is 41.45. In terms of profitability, LMDXW's ROE is -15.58%, compared to PKI's ROE of +0.03%. Regarding short-term risk, LMDXW is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
LMDXW vs ICLR Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while ICLR trades at $161.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas ICLR's P/E ratio is 13.19. In terms of profitability, LMDXW's ROE is -15.58%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, LMDXW is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
LMDXW vs QGEN Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, QGEN has a market cap of 9.4B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while QGEN trades at $45.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas QGEN's P/E ratio is 18.87. In terms of profitability, LMDXW's ROE is -15.58%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, LMDXW is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
LMDXW vs GRAL Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while GRAL trades at $137.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas GRAL's P/E ratio is -14.08. In terms of profitability, LMDXW's ROE is -15.58%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, LMDXW is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
LMDXW vs RDNT Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while RDNT trades at $70.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas RDNT's P/E ratio is 152.78. In terms of profitability, LMDXW's ROE is -15.58%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, LMDXW is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
LMDXW vs SHC Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while SHC trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas SHC's P/E ratio is 19.01. In terms of profitability, LMDXW's ROE is -15.58%, compared to SHC's ROE of +0.27%. Regarding short-term risk, LMDXW is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
LMDXW vs BLLN Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, BLLN has a market cap of 4.6B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while BLLN trades at $99.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas BLLN's P/E ratio is 142.72. In terms of profitability, LMDXW's ROE is -15.58%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, LMDXW is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
LMDXW vs SYNH Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas SYNH's P/E ratio is 61.40. In terms of profitability, LMDXW's ROE is -15.58%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, LMDXW is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
LMDXW vs VCYT Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while VCYT trades at $44.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas VCYT's P/E ratio is 22.33. In terms of profitability, LMDXW's ROE is -15.58%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, LMDXW is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
LMDXW vs CDNA Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while CDNA trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas CDNA's P/E ratio is 75.94. In terms of profitability, LMDXW's ROE is -15.58%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, LMDXW is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
LMDXW vs OLK Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas OLK's P/E ratio is -96.59. In terms of profitability, LMDXW's ROE is -15.58%, compared to OLK's ROE of -0.07%. Regarding short-term risk, LMDXW is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
LMDXW vs WGS Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while WGS trades at $71.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas WGS's P/E ratio is 198.67. In terms of profitability, LMDXW's ROE is -15.58%, compared to WGS's ROE of -0.39%. Regarding short-term risk, LMDXW is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
LMDXW vs PSNL Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while PSNL trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas PSNL's P/E ratio is -14.71. In terms of profitability, LMDXW's ROE is -15.58%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, LMDXW is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
LMDXW vs OPK Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while OPK trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas OPK's P/E ratio is -16.22. In terms of profitability, LMDXW's ROE is -15.58%, compared to OPK's ROE of -0.06%. Regarding short-term risk, LMDXW is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
LMDXW vs CSTL Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while CSTL trades at $33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas CSTL's P/E ratio is -50.55. In terms of profitability, LMDXW's ROE is -15.58%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, LMDXW is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
LMDXW vs FLGT Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, FLGT has a market cap of 584.5M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while FLGT trades at $20.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas FLGT's P/E ratio is 2058.00. In terms of profitability, LMDXW's ROE is -15.58%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, LMDXW is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
LMDXW vs GRALV Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas GRALV's P/E ratio is N/A. In terms of profitability, LMDXW's ROE is -15.58%, compared to GRALV's ROE of N/A. Regarding short-term risk, LMDXW is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
LMDXW vs NEO Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, NEO has a market cap of 424.1M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while NEO trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas NEO's P/E ratio is 126.96. In terms of profitability, LMDXW's ROE is -15.58%, compared to NEO's ROE of -0.06%. Regarding short-term risk, LMDXW is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
LMDXW vs MYGN Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, MYGN has a market cap of 404.2M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while MYGN trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas MYGN's P/E ratio is -32.92. In terms of profitability, LMDXW's ROE is -15.58%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, LMDXW is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
LMDXW vs CO Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas CO's P/E ratio is 5.06. In terms of profitability, LMDXW's ROE is -15.58%, compared to CO's ROE of +0.11%. Regarding short-term risk, LMDXW is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for LMDXW.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
LMDXW vs FLDM Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas FLDM's P/E ratio is -4.74. In terms of profitability, LMDXW's ROE is -15.58%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, LMDXW is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
LMDXW vs BDSX Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, BDSX has a market cap of 227.6M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while BDSX trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas BDSX's P/E ratio is -8.82. In terms of profitability, LMDXW's ROE is -15.58%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, LMDXW is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
LMDXW vs XGN Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, XGN has a market cap of 197.9M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while XGN trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas XGN's P/E ratio is -10.11. In terms of profitability, LMDXW's ROE is -15.58%, compared to XGN's ROE of -1.22%. Regarding short-term risk, LMDXW is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
LMDXW vs FRNM Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, FRNM has a market cap of 133.5M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while FRNM trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas FRNM's P/E ratio is N/A. In terms of profitability, LMDXW's ROE is -15.58%, compared to FRNM's ROE of N/A. Regarding short-term risk, LMDXW is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
LMDXW vs GTH Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas GTH's P/E ratio is -1.11. In terms of profitability, LMDXW's ROE is -15.58%, compared to GTH's ROE of -1.01%. Regarding short-term risk, LMDXW is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
LMDXW vs GENE Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas GENE's P/E ratio is -38.25. In terms of profitability, LMDXW's ROE is -15.58%, compared to GENE's ROE of -1.85%. Regarding short-term risk, LMDXW is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
LMDXW vs IMDX Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas IMDX's P/E ratio is -2.27. In terms of profitability, LMDXW's ROE is -15.58%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, LMDXW is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
LMDXW vs SERA Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while SERA trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas SERA's P/E ratio is -3.15. In terms of profitability, LMDXW's ROE is -15.58%, compared to SERA's ROE of -0.47%. Regarding short-term risk, LMDXW is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
LMDXW vs PRPO Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, PRPO has a market cap of 41.8M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while PRPO trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas PRPO's P/E ratio is -36.08. In terms of profitability, LMDXW's ROE is -15.58%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, LMDXW is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
LMDXW vs MDXH Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, MDXH has a market cap of 30.8M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while MDXH trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas MDXH's P/E ratio is -0.82. In terms of profitability, LMDXW's ROE is -15.58%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, LMDXW is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
LMDXW vs QUCY Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas QUCY's P/E ratio is -0.06. In terms of profitability, LMDXW's ROE is -15.58%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, LMDXW is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
LMDXW vs AKU Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas AKU's P/E ratio is -0.13. In terms of profitability, LMDXW's ROE is -15.58%, compared to AKU's ROE of -5.32%. Regarding short-term risk, LMDXW is more volatile compared to AKU. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
LMDXW vs BNR Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, BNR has a market cap of 17.4M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while BNR trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas BNR's P/E ratio is -18.97. In terms of profitability, LMDXW's ROE is -15.58%, compared to BNR's ROE of -0.13%. Regarding short-term risk, LMDXW is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
LMDXW vs CEMI Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas CEMI's P/E ratio is -0.63. In terms of profitability, LMDXW's ROE is -15.58%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, LMDXW is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
LMDXW vs ENZ Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas ENZ's P/E ratio is -2.24. In terms of profitability, LMDXW's ROE is -15.58%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, LMDXW is more volatile compared to ENZ. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
LMDXW vs PMD Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas PMD's P/E ratio is -5.24. In terms of profitability, LMDXW's ROE is -15.58%, compared to PMD's ROE of -0.32%. Regarding short-term risk, LMDXW is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
LMDXW vs ME Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas ME's P/E ratio is -0.03. In terms of profitability, LMDXW's ROE is -15.58%, compared to ME's ROE of -3.47%. Regarding short-term risk, LMDXW is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
LMDXW vs MYNZ Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, LMDXW's ROE is -15.58%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, LMDXW is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
LMDXW vs BIAFW Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, BIAFW has a market cap of 12.1M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while BIAFW trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas BIAFW's P/E ratio is 1.29. In terms of profitability, LMDXW's ROE is -15.58%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, LMDXW is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
LMDXW vs CHEK Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas CHEK's P/E ratio is -0.43. In terms of profitability, LMDXW's ROE is -15.58%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, LMDXW is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
LMDXW vs CNTG Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas CNTG's P/E ratio is -0.23. In terms of profitability, LMDXW's ROE is -15.58%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, LMDXW is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
LMDXW vs ADVB Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas ADVB's P/E ratio is -58.00. In terms of profitability, LMDXW's ROE is -15.58%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, LMDXW is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
LMDXW vs NDRA Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas NDRA's P/E ratio is -0.90. In terms of profitability, LMDXW's ROE is -15.58%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, LMDXW is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
LMDXW vs APDN Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas APDN's P/E ratio is -0.10. In terms of profitability, LMDXW's ROE is -15.58%, compared to APDN's ROE of -7.23%. Regarding short-term risk, LMDXW is more volatile compared to APDN. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
LMDXW vs NVTA Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas NVTA's P/E ratio is -0.00. In terms of profitability, LMDXW's ROE is -15.58%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, LMDXW is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for LMDXW.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
LMDXW vs LMDX Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas LMDX's P/E ratio is -0.01. In terms of profitability, LMDXW's ROE is -15.58%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, LMDXW is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for LMDXW.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
LMDXW vs DMTK Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas DMTK's P/E ratio is -0.04. In terms of profitability, LMDXW's ROE is -15.58%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, LMDXW is more volatile compared to DMTK. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
LMDXW vs NOTV Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas NOTV's P/E ratio is -0.03. In terms of profitability, LMDXW's ROE is -15.58%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, LMDXW is more volatile compared to NOTV. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
LMDXW vs ISPC Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, ISPC has a market cap of 2.7M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while ISPC trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas ISPC's P/E ratio is -0.03. In terms of profitability, LMDXW's ROE is -15.58%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, LMDXW is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
LMDXW vs BIAF Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas BIAF's P/E ratio is -0.71. In terms of profitability, LMDXW's ROE is -15.58%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, LMDXW is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
LMDXW vs SQL Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas SQL's P/E ratio is -0.40. In terms of profitability, LMDXW's ROE is -15.58%, compared to SQL's ROE of -30.46%. Regarding short-term risk, LMDXW is more volatile compared to SQL. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
LMDXW vs AWH Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas AWH's P/E ratio is -0.09. In terms of profitability, LMDXW's ROE is -15.58%, compared to AWH's ROE of +1.62%. Regarding short-term risk, LMDXW is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
LMDXW vs HTGM Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas HTGM's P/E ratio is -0.03. In terms of profitability, LMDXW's ROE is -15.58%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, LMDXW is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
LMDXW vs BIOC Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas BIOC's P/E ratio is -0.01. In terms of profitability, LMDXW's ROE is -15.58%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, LMDXW is more volatile compared to BIOC. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
LMDXW vs SQLLW Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, LMDXW's ROE is -15.58%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, LMDXW is more volatile compared to SQLLW. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
LMDXW vs WGSWW Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, LMDXW's ROE is -15.58%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, LMDXW is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
LMDXW vs OCDX Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas OCDX's P/E ratio is -42.28. In terms of profitability, LMDXW's ROE is -15.58%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, LMDXW is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
LMDXW vs DHR-PA Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, LMDXW's ROE is -15.58%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, LMDXW is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check DHR-PA's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
LMDXW vs BNGOW Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas BNGOW's P/E ratio is N/A. In terms of profitability, LMDXW's ROE is -15.58%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, LMDXW is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for LMDXW.Check BNGOW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
LMDXW vs PRXL Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas PRXL's P/E ratio is 42.97. In terms of profitability, LMDXW's ROE is -15.58%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, LMDXW is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check PRXL's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
LMDXW vs CHEKZ Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, LMDXW's ROE is -15.58%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, LMDXW is more volatile compared to CHEKZ. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
LMDXW vs MEUSW Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas MEUSW's P/E ratio is N/A. In terms of profitability, LMDXW's ROE is -15.58%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, LMDXW is more volatile compared to MEUSW. This indicates higher risk in terms of short-term price fluctuations for LMDXW.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
LMDXW vs NDRAW Comparison October 2026
LumiraDx Limited (NASDAQ: LMDXW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMDXW stands at 5.1M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, LMDXW is priced at $0.00 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMDXW currently has a P/E ratio of -0.00, whereas NDRAW's P/E ratio is N/A. In terms of profitability, LMDXW's ROE is -15.58%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, LMDXW is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for LMDXW.Check NDRAW's competition here